Sei Investments Co. Raises Holdings in Sanofi (NASDAQ:SNY)

Sei Investments Co. lifted its holdings in Sanofi (NASDAQ:SNY) by 8.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 644,302 shares of the company’s stock after purchasing an additional 47,801 shares during the quarter. Sei Investments Co.’s holdings in Sanofi were worth $31,075,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Raymond James Financial Inc. bought a new position in shares of Sanofi during the 4th quarter valued at $135,933,000. Boston Partners lifted its holdings in Sanofi by 86.4% in the fourth quarter. Boston Partners now owns 5,396,531 shares of the company’s stock valued at $260,607,000 after acquiring an additional 2,501,073 shares during the period. Magnetar Financial LLC boosted its position in Sanofi by 104.3% in the fourth quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company’s stock worth $161,103,000 after purchasing an additional 1,705,148 shares during the last quarter. DAVENPORT & Co LLC grew its stake in shares of Sanofi by 40.7% during the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock valued at $110,715,000 after purchasing an additional 664,455 shares during the period. Finally, Thrivent Financial for Lutherans increased its position in shares of Sanofi by 36.0% during the 4th quarter. Thrivent Financial for Lutherans now owns 1,943,761 shares of the company’s stock valued at $93,774,000 after purchasing an additional 514,542 shares during the last quarter. 14.04% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on SNY. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. The Goldman Sachs Group began coverage on Sanofi in a research note on Friday, March 21st. They issued a “neutral” rating and a $65.00 price objective for the company. Finally, Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Three research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Sanofi presently has an average rating of “Moderate Buy” and a consensus price target of $62.50.

Sanofi Stock Down 0.9 %

NASDAQ SNY opened at $55.45 on Wednesday. Sanofi has a 12 month low of $45.22 and a 12 month high of $60.12. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The stock has a market cap of $140.72 billion, a PE ratio of 22.27, a P/E/G ratio of 1.01 and a beta of 0.58. The stock’s 50 day moving average is $54.84 and its 200 day moving average is $52.82.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Research analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.